Tag:
Impax Laboratories
Latest Headlines
Latest Headlines
Impax licenses U.S. rights to AstraZeneca migraine drug, variations likely
Impax Pharmaceuticals is paying AstraZeneca ( $AZN ) $130 million so it can license U.S. commercial rights for three versions of the migraine drug Zomig. Their agreement also allows for new variations
Shire blames Adderall shortage on DEA
Shire's attention deficit drug Adderall is running short in the U.S. So who's to blame? Shire says the Drug Enforcement Agency, which regulates the active ingredient in Adderall, dragged its feet on
Good news, bad news for Impax
The FDA has given tentative approval for an ANDA for a generic version of Eli Lilly's Cymbalta, a drug that treats depression and general anxiety. At the heart of the new drug is Impax Laboratories'
Merck sues to block Impax version of Vytorin
Merck ( NYSE: MRK ) is fighting back against an Impax Laboratories bid to cut in on its cholesterol drug Vytorin . The drugmaker has sued the generics firm to protect the blockbuster med, to which it
FDA may withdraw another fast-track med
Another fast-track drug is under FDA scrutiny. The Shire blood-pressure drug ProAmantine won agency approval in 1996 under its accelerated approval process. But follow-up studies required by that
Genzyme, Impax begin Revela patent fight
Genzyme sued Impax Laboratories for patent infringement after Impax filed for FDA approval of a copycat version of the kidney dialysis drug Renvela. Report
Judge won't toss suit over Wellbutrin generics
FDA approval doesn't shield generic drugmakers from lawsuits, either, a federal judge ruled in refusing to dismiss a case against Teva Pharmaceutical Industries ( NASDAQ: TEVA ) and Impax Laboratories (
Ranbaxy flubs launch of generic Flomax
Ranbaxy Laboratories has run up against regulatory troubles yet again. The company was supposed to be set for a March 2 launch of generic Flomax, the Astellas Pharma urology drug. As first to file
Novartis, Medicis cut generics deals
The march of the authorized generic deal continues with two new pacts between brand-name drugmakers and their copycats. In both cases, the generics makers will be able launch their versions of the
